Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: An observational prospective study
Fig 3
Trends of mid-regional pro-adrenomedullin (MR-proADM) from ICU admission (day 0) to day 14 in survivor (white) and non-survivor (grey) patients who required VV-ECMO.
Time dependent analysis of MR-proADM was significantly different between survivors and non-survivors (p-value 0.042) but it was not over the time (p-value 0.205).